{"id": "HPRD50.d3.s1_HPRD50.d3.s1.p0", "text": "RESULTS: Tyrosine phosphorylation of p85 is upregulated by IL-6 in both LNCaP and PC-3", "text_with_entity_marker": "RESULTS: Tyrosine phosphorylation of p85 is upregulated by [E1]IL-6[/E1] in both LNCaP and [E2]PC-3[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[59, 63]], "entity_1_idx_in_text_with_entity_marker": [63, 67], "entity_1_type": "pm0110911", "entity_1_type_id": 11, "entity_2": "PC-3", "entity_2_idx": [[82, 86]], "entity_2_idx_in_text_with_entity_marker": [95, 99], "entity_2_type": "pm0107379||pm0107715||pm0114827", "entity_2_type_id": 13}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p1", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized [E1]FGFR4[/E1] also bound FGF-8 besides [E2]FGF-1[/E2] and FGF-2", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR4", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "pm0119069", "entity_1_type_id": 18, "entity_2": "FGF-1", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "pm0124654", "entity_2_type_id": 16}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p2", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized [E1]FGFR4[/E1] also bound FGF-8 besides FGF-1 and [E2]FGF-2[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR4", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "pm0119069", "entity_1_type_id": 18, "entity_2": "FGF-2", "entity_2_idx": [[53, 58]], "entity_2_idx_in_text_with_entity_marker": [66, 71], "entity_2_type": "pm0106166", "entity_2_type_id": 17}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p4", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized FGFR4 also bound [E1]FGF-8[/E1] besides FGF-1 and [E2]FGF-2[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-8", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "pm0118903", "entity_1_type_id": 19, "entity_2": "FGF-2", "entity_2_idx": [[53, 58]], "entity_2_idx_in_text_with_entity_marker": [66, 71], "entity_2_type": "pm0106166", "entity_2_type_id": 17}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s2_HPRD50.d6.s2.p2", "text": "Pituitary GH triggered the tyrosine phosphorylation of Janus kinase 2 (Jak2) and STAT3 in neutrophils", "text_with_entity_marker": "Pituitary GH triggered the tyrosine phosphorylation of Janus kinase 2 ([E1]Jak2[/E1]) and [E2]STAT3[/E2] in neutrophils", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "STAT3", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "pm0118656", "entity_2_type_id": 25}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s3_HPRD50.d6.s3.p1", "text": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Jak2, STAT3, p125FAK, and paxillin phosphorylation", "text_with_entity_marker": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and [E1]Jak2[/E1], STAT3, p125FAK, and [E2]paxillin[/E2] phosphorylation", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[98, 102]], "entity_1_idx_in_text_with_entity_marker": [102, 106], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "paxillin", "entity_2_idx": [[124, 132]], "entity_2_idx_in_text_with_entity_marker": [137, 145], "entity_2_type": "pm0119378", "entity_2_type_id": 24}], "directed": false, "reverse": false}
{"id": "HPRD50.d9.s0_HPRD50.d9.s0.p2", "text": "Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)", "text_with_entity_marker": "Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical [E1]Syt[/E1] (named [E2]Syt XIII[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syt", "entity_1_idx": [[94, 97]], "entity_1_idx_in_text_with_entity_marker": [98, 101], "entity_1_type": "pm0109470||pm0116152", "entity_1_type_id": 35, "entity_2": "Syt XIII", "entity_2_idx": [[105, 113]], "entity_2_idx_in_text_with_entity_marker": [118, 126], "entity_2_type": "pm0110335", "entity_2_type_id": 34}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s0_HPRD50.d10.s0.p2", "text": "Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1)", "text_with_entity_marker": "Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor [E1]sialoadhesin[/E1] ([E2]Siglec-1[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sialoadhesin", "entity_1_idx": [[94, 106]], "entity_1_idx_in_text_with_entity_marker": [98, 110], "entity_1_type": "pm0108007", "entity_1_type_id": 37, "entity_2": "Siglec-1", "entity_2_idx": [[108, 116]], "entity_2_idx_in_text_with_entity_marker": [121, 129], "entity_2_type": "pm0108007", "entity_2_type_id": 37}], "directed": false, "reverse": false}
{"id": "HPRD50.d12.s1_HPRD50.d12.s1.p0", "text": "In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner", "text_with_entity_marker": "In this report, we demonstrate the stable association of [E1]PLCgamma1[/E1] with [E2]AP180[/E2] in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PLCgamma1", "entity_1_idx": [[57, 66]], "entity_1_idx_in_text_with_entity_marker": [61, 70], "entity_1_type": "pm0126499", "entity_1_type_id": 42, "entity_2": "AP180", "entity_2_idx": [[72, 77]], "entity_2_idx_in_text_with_entity_marker": [85, 90], "entity_2_type": "pm0106306", "entity_2_type_id": 41}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p0", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of [E1]CLIP-170[/E1] results in a zinc finger-dependent localization of a [E2]phospho-LIS1[/E2] isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CLIP-170", "entity_1_idx": [[18, 26]], "entity_1_idx_in_text_with_entity_marker": [22, 30], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "phospho-LIS1", "entity_2_idx": [[80, 92]], "entity_2_idx_in_text_with_entity_marker": [93, 105], "entity_2_type": "phospho-pm0110467", "entity_2_type_id": 45}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p4", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a [E1]phospho-LIS1[/E1] isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and [E2]LIS1[/E2] regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phospho-LIS1", "entity_1_idx": [[80, 92]], "entity_1_idx_in_text_with_entity_marker": [84, 96], "entity_1_type": "phospho-pm0110467", "entity_1_type_id": 45, "entity_2": "LIS1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0110467", "entity_2_type_id": 44}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s3_HPRD50.d15.s3.p0", "text": "In addition, GPI-80 was immunoprecipitated from human neutrophil lysates by anti-human CD18 mAb", "text_with_entity_marker": "In addition, [E1]GPI-80[/E1] was immunoprecipitated from human neutrophil lysates by anti-human [E2]CD18[/E2] mAb", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GPI-80", "entity_1_idx": [[13, 19]], "entity_1_idx_in_text_with_entity_marker": [17, 23], "entity_1_type": "pm0100260", "entity_1_type_id": 49, "entity_2": "CD18", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "pm0105418||pm0114514", "entity_2_type_id": 50}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s0_HPRD50.d16.s0.p1", "text": "GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "text_with_entity_marker": "[E1]GADD45b[/E1] and GADD45g are [E2]cdc2[/E2]/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GADD45b", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "cdc2", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s0_HPRD50.d18.s0.p2", "text": "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)", "text_with_entity_marker": "The transmembrane receptor protein tyrosine phosphatase [E1]DEP1[/E1] interacts with [E2]p120(ctn)[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DEP1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0115917", "entity_1_type_id": 59, "entity_2": "p120(ctn)", "entity_2_idx": [[76, 85]], "entity_2_idx_in_text_with_entity_marker": [89, 98], "entity_2_type": "pm0101886", "entity_2_type_id": 60}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s1_HPRD50.d18.s1.p2", "text": "The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "text_with_entity_marker": "The receptor-like protein tyrosine phosphatase [E1]DEP1[/E1], also known as [E2]CD148[/E2], is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "DEP1", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "pm0115917", "entity_1_type_id": 59, "entity_2": "CD148", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p2", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "[E1]p300[/E1]/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A ([E2]MEF2A[/E2]) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "MEF2A", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p4", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "p300/[E1]cAMP-response-element-binding-protein[/E1] ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A ([E2]MEF2A[/E2]) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cAMP-response-element-binding-protein", "entity_1_idx": [[5, 42]], "entity_1_idx_in_text_with_entity_marker": [9, 46], "entity_1_type": "pm0100874", "entity_1_type_id": 66, "entity_2": "MEF2A", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s0_HPRD50.d20.s0.p2", "text": "The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The human Imp3 and [E1]Imp4[/E1] proteins form a ternary complex with hMpp10, which only interacts with the U3 [E2]snoRNA[/E2] in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Imp4", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "pm0104160||pm0117832", "entity_1_type_id": 69, "entity_2": "snoRNA", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "pm0114346", "entity_2_type_id": 70}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s0_HPRD50.d21.s0.p2", "text": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system", "text_with_entity_marker": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the [E1]orexin 1 receptor[/E1] ([E2]OX1R[/E2]) using a heterologous system", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "orexin 1 receptor", "entity_1_idx": [[102, 119]], "entity_1_idx_in_text_with_entity_marker": [106, 123], "entity_1_type": "pm0111533", "entity_1_type_id": 72, "entity_2": "OX1R", "entity_2_idx": [[121, 125]], "entity_2_idx_in_text_with_entity_marker": [134, 138], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s1_HPRD50.d21.s1.p2", "text": "In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R", "text_with_entity_marker": "In contrast to OX1R, the potency of direct activation of [E1]CB1[/E1] was not affected by co-expression with [E2]OX1R[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CB1", "entity_1_idx": [[57, 60]], "entity_1_idx_in_text_with_entity_marker": [61, 64], "entity_1_type": "pm0109721", "entity_1_type_id": 71, "entity_2": "OX1R", "entity_2_idx": [[100, 104]], "entity_2_idx_in_text_with_entity_marker": [113, 117], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s5_HPRD50.d22.s5.p2", "text": "The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro", "text_with_entity_marker": "The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, [E1]Rac1[/E1], and [E2]Cdc42[/E2] in vitro", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rac1", "entity_1_idx": [[101, 105]], "entity_1_idx_in_text_with_entity_marker": [105, 109], "entity_1_type": "pm0109115", "entity_1_type_id": 83, "entity_2": "Cdc42", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s6_HPRD50.d22.s6.p1", "text": "The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42", "text_with_entity_marker": "The protein was named [E1]GC-GAP[/E1] for its ability to interact with GAB proteins and its activity toward Rac and [E2]Cdc42[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[22, 28]], "entity_1_idx_in_text_with_entity_marker": [26, 32], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Cdc42", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s7_HPRD50.d22.s7.p2", "text": "Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA", "text_with_entity_marker": "Expression of GC-GAP in 293T cells led to a reduction in active [E1]Rac1[/E1] and [E2]Cdc42[/E2] levels but not RhoA", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rac1", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "pm0109115", "entity_1_type_id": 83, "entity_2": "Cdc42", "entity_2_idx": [[73, 78]], "entity_2_idx_in_text_with_entity_marker": [86, 91], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p13", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates [E1]NudC[/E1] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[91, 95]], "entity_1_idx_in_text_with_entity_marker": [95, 99], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p0", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of [E1]NudC[/E1] by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type [E2]NudC[/E2], but not by NudC with mutations in the Plk1 phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[200, 204]], "entity_2_idx_in_text_with_entity_marker": [213, 217], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p2", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of [E1]NudC[/E1] by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the [E2]Plk1[/E2] phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p0", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the [E1]LDL receptor[/E1] ([E2]LDLR[/E2]) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LDL receptor", "entity_1_idx": [[56, 68]], "entity_1_idx_in_text_with_entity_marker": [60, 72], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "LDLR", "entity_2_idx": [[70, 74]], "entity_2_idx_in_text_with_entity_marker": [83, 87], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s3_HPRD50.d26.s3.p0", "text": "Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1", "text_with_entity_marker": "Overexpression of [E1]TBP-1[/E1] promotes degradation of [E2]Hif1 alpha[/E2] in a pVHL-dependent manner that requires the ATPase domain of TBP-1", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP-1", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "Hif1 alpha", "entity_2_idx": [[48, 58]], "entity_2_idx_in_text_with_entity_marker": [61, 71], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p8", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with [E1]TBP-1[/E1] and suggests a new mechanism for Hif1 alpha stabilization in some [E2]pVHL[/E2]-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP-1", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "pVHL", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s3_HPRD50.d28.s3.p0", "text": "In addition, both MSH2 and Rad17 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of SMC1 is required for cellular survival", "text_with_entity_marker": "In addition, both [E1]MSH2[/E1] and [E2]Rad17[/E2] are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of SMC1 is required for cellular survival", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MSH2", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0121865", "entity_1_type_id": 99, "entity_2": "Rad17", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "pm0117336", "entity_2_type_id": 102}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s3_HPRD50.d28.s3.p1", "text": "In addition, both MSH2 and Rad17 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of SMC1 is required for cellular survival", "text_with_entity_marker": "In addition, both [E1]MSH2[/E1] and Rad17 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of [E2]SMC1[/E2] is required for cellular survival", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MSH2", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0121865", "entity_1_type_id": 99, "entity_2": "SMC1", "entity_2_idx": [[161, 165]], "entity_2_idx_in_text_with_entity_marker": [174, 178], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p2", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that [E1]Dnmt3a[/E1] interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and [E2]PIASxalpha[/E2], all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "PIASxalpha", "entity_2_idx": [[167, 177]], "entity_2_idx_in_text_with_entity_marker": [180, 190], "entity_2_type": "pm0119764", "entity_2_type_id": 107}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p4", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans (perlecan, [E1]biglycan[/E1], decorin, and [E2]versican[/E2]) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "biglycan", "entity_1_idx": [[71, 79]], "entity_1_idx_in_text_with_entity_marker": [75, 83], "entity_1_type": "pm0124379", "entity_1_type_id": 115, "entity_2": "versican", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p0", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of [E1]perlecan[/E1], a specific [E2]heparan sulfate proteoglycan[/E2], to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "heparan sulfate proteoglycan", "entity_2_idx": [[82, 110]], "entity_2_idx_in_text_with_entity_marker": [95, 123], "entity_2_type": "pm0112250", "entity_2_type_id": 118}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p4", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived [E1]PGs[/E1] to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with [E2]perlecan[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[143, 146]], "entity_1_idx_in_text_with_entity_marker": [147, 150], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "perlecan", "entity_2_idx": [[290, 298]], "entity_2_idx_in_text_with_entity_marker": [303, 311], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p17", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E1]decorin[/E1] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decorin", "entity_1_idx": [[111, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 122], "entity_1_type": "pm0108608", "entity_1_type_id": 116, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s1_HPRD50.d33.s1.p0", "text": "However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53", "text_with_entity_marker": "However, cytokines, in particular [E1]IL-2[/E1] and [E2]IL-4[/E2], potentiated the DNA synthesis induced by cross-linking of CD53", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "pm0110478", "entity_1_type_id": 128, "entity_2": "IL-4", "entity_2_idx": [[43, 47]], "entity_2_idx_in_text_with_entity_marker": [56, 60], "entity_2_type": "pm0106845", "entity_2_type_id": 129}], "directed": false, "reverse": false}
{"id": "HPRD50.d34.s1_HPRD50.d34.s1.p1", "text": "The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans", "text_with_entity_marker": "The fact that the [E1]apoB[/E1] mRNA editing protein also exists as a homodimer has important implications for the mechanism of [E2]apoB[/E2] mRNA editing in humans", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "apoB", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0126272", "entity_1_type_id": 130, "entity_2": "apoB", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "pm0126272", "entity_2_type_id": 130}], "directed": false, "reverse": false}
{"id": "HPRD50.d35.s1_HPRD50.d35.s1.p0", "text": "We used cDNA probes for the Etfdh, Etfb, and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13", "text_with_entity_marker": "We used cDNA probes for the [E1]Etfdh[/E1], [E2]Etfb[/E2], and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Etfdh", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "pm0103481", "entity_1_type_id": 133, "entity_2": "Etfb", "entity_2_idx": [[35, 39]], "entity_2_idx_in_text_with_entity_marker": [48, 52], "entity_2_type": "pm0110405", "entity_2_type_id": 134}], "directed": false, "reverse": false}
{"id": "HPRD50.d37.s0_HPRD50.d37.s0.p0", "text": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "text_with_entity_marker": "[E1]TFIID[/E1] dimers formed through self-association of the TATA-binding polypeptide ([E2]TBP[/E2]) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0109127", "entity_1_type_id": 137, "entity_2": "TBP", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0109127", "entity_2_type_id": 137}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p5", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including [E1]cystatin alpha[/E1], [E2]desmoplakin[/E2], elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cystatin alpha", "entity_1_idx": [[171, 185]], "entity_1_idx_in_text_with_entity_marker": [175, 189], "entity_1_type": "pm0104526", "entity_1_type_id": 140, "entity_2": "desmoplakin", "entity_2_idx": [[187, 198]], "entity_2_idx_in_text_with_entity_marker": [200, 211], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p13", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, [E1]elafin[/E1], keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elafin", "entity_1_idx": [[200, 206]], "entity_1_idx_in_text_with_entity_marker": [204, 210], "entity_1_type": "pm0114270", "entity_1_type_id": 142, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d40.s0_HPRD50.d40.s0.p0", "text": "Transient expression of the full-length E2-2 without RSRS in U1240MG glioblastoma cells resulted in repression of FGF-1.B promoter activity", "text_with_entity_marker": "Transient expression of the full-length [E1]E2-2[/E1] without RSRS in U1240MG glioblastoma cells resulted in repression of [E2]FGF-1.B[/E2] promoter activity", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2-2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "pm0110165", "entity_1_type_id": 148, "entity_2": "FGF-1.B", "entity_2_idx": [[114, 121]], "entity_2_idx_in_text_with_entity_marker": [127, 134], "entity_2_type": "pm0124654-1.B", "entity_2_type_id": 149}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s1_HPRD50.d42.s1.p0", "text": "In contrast to IkappaBbeta, Bcl3 did not interact with the AF2 domain of RXR", "text_with_entity_marker": "In contrast to [E1]IkappaBbeta[/E1], [E2]Bcl3[/E2] did not interact with the AF2 domain of RXR", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IkappaBbeta", "entity_1_idx": [[15, 26]], "entity_1_idx_in_text_with_entity_marker": [19, 30], "entity_1_type": "pm0122183", "entity_1_type_id": 152, "entity_2": "Bcl3", "entity_2_idx": [[28, 32]], "entity_2_idx_in_text_with_entity_marker": [41, 45], "entity_2_type": "pm0126712", "entity_2_type_id": 151}], "directed": false, "reverse": false}
